Vaxcyte (PCVX) Liabilities and Shareholders Equity (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $3.3 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 0.88% year-over-year to $3.3 billion in Q1 2026; TTM through Mar 2026 was $12.8 billion, a 2.33% increase from a year earlier, with the FY2025 full-year figure at $3.0 billion, down 14.48% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $3.3 billion, up from $3.0 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for PCVX reached as high as $3.6 billion in Q3 2024 and fell as low as $402.7 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $2.1 billion across 5 years, with a median of $2.1 billion in 2024.
• Across the five-year window, Liabilities and Shareholders Equity surged 265.1% in 2023 and fell 14.48% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.0 billion in 2022, then soared by 39.93% to $1.4 billion in 2023, then surged by 149.4% to $3.5 billion in 2024, then decreased by 14.48% to $3.0 billion in 2025, then gained by 11.51% to $3.3 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $3.3 billion in Q1 2026, $3.0 billion in Q4 2025, and $3.2 billion in Q3 2025.